Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase NA 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 17NIH 10INDUSTRY 7NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Lung Neoplasms 64Breast Neoplasms 63Lymphoma 58Ovarian Neoplasms 51Leukemia 44Sarcoma 43Prostatic Neoplasms 39Multiple Myeloma 36Head and Neck Neoplasms 36Central Nervous System Neoplasms 36Squamous Cell Carcinoma of Head and Neck 32Colorectal Neoplasms 31Carcinoma, Ovarian Epithelial 30Melanoma 29Rectal Neoplasms 28Neoplasm Metastasis 27Uterine Cervical Neoplasms 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lymphoma, Large B-Cell, Diffuse 26Brain Neoplasms 26Urinary Bladder Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 24Leukemia, Myeloid, Acute 23Fallopian Tube Neoplasms 23Endometrial Neoplasms 22Glioblastoma 21Adenocarcinoma of Lung 21Lymphoma, Mantle-Cell 18Gliosarcoma 17

Interventions

nintedanib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × Carcinoma, Medullary × Clear all
NCT01788982 2020-07-31

Nintedanib(BIBF1120) in Thyroid Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
100 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

NCT01736878 2013-05-17

SUMMIT

Eanm Research Ltd

Phase 2 Withdrawn

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡